Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

Company Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Key Stats

• Today's Range: $48.78 to $50.95
• 50-Day Range: $38.39 to $50.70
• 52-Week Range: $28.56 to $54.23
• Volume: 526,507 shs
• Average Volume: 496,948 shs
• Market Capitalization: $2.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $65.50
• Consensus Rating: Buy

Mirum Pharmaceuticals Stock Analysis - MarketRank™

Mirum Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 411th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Mirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mirum Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.43) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mirum Pharmaceuticals is -31.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mirum Pharmaceuticals is -31.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mirum Pharmaceuticals has a P/B Ratio of 10.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.37% of the float of Mirum Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Mirum Pharmaceuticals has recently decreased by 3.66%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mirum Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Mirum Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.69

Percentage of Shares Shorted

16.37% of the float of Mirum Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Mirum Pharmaceuticals has recently decreased by 3.66%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.89

News Sentiment

Mirum Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Mirum Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mirum Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.87% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

MIRM Stock Analysis - Frequently Asked Questions

How have MIRM shares performed this year?

Mirum Pharmaceuticals' stock was trading at $41.35 at the start of the year. Since then, MIRM shares have increased by 22.6% and is now trading at $50.70.
View the best growth stocks for 2025 here.

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.05. The company's revenue was up 61.2% compared to the same quarter last year.
Read the conference call transcript.

When did Mirum Pharmaceuticals IPO?

Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Who are Mirum Pharmaceuticals' major shareholders?

Top institutional shareholders of Mirum Pharmaceuticals include Frazier Life Sciences Management L.P. (13.72%), Vanguard Group Inc. (5.14%), Eventide Asset Management LLC (5.10%) and Price T Rowe Associates Inc. MD (2.86%). Insiders that own company stock include Niall O'donnell, Patrick J Heron, Christopher Peetz, Lara Longpre, Pamela Vig, Peter Radovich, Eric Bjerkholt, Joanne Quan, Jolanda Howe, Saira Ramasastry and Michael G Grey.
View institutional ownership trends.

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

• Last Earnings: 5/14/2025
• Today: 6/18/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MIRM
• CIK: 1759425
• Web: mirumpharma.com
• Phone: (650) 667-4085
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $65.50
• High Stock Price Target: $77.00
• Low Stock Price Target: $49.00
• Potential Upside/Downside: +29.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$87.94 million
• Net Margins: -20.39%
• Pretax Margin: -20.01%
• Return on Equity: -33.63%
• Return on Assets: -11.50%

Debt

• Debt-to-Equity Ratio: 1.32
• Current Ratio: 3.22
• Quick Ratio: 3.04

Sales & Book Value

• Annual Sales: $336.89 million
• Price / Sales: 7.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.70 per share
• Price / Book: 10.79

Miscellaneous

• Outstanding Shares: 49,530,000
• Free Float: 38,206,000
• Market Cap: $2.51 billion
• Optionable: Optionable
• Beta: 0.95